Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer

In advanced non-small cell lung cancer (NSCLC), response to immunotherapy is difficult to predict from pre-treatment information. Given the toxicity of immunotherapy and its financial burden on the healthcare system, we set out to identify patients for whom treatment is effective. To this end, we us...

Descripción completa

Detalles Bibliográficos
Autores principales: Donker, H. C., van Es, B., Tamminga, M., Lunter, G. A., van Kempen, L. C. L. T., Schuuring, E., Hiltermann, T. J. N., Groen, H. J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121673/
https://www.ncbi.nlm.nih.gov/pubmed/37085581
http://dx.doi.org/10.1038/s41598-023-32499-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121673/
https://www.ncbi.nlm.nih.gov/pubmed/37085581
http://dx.doi.org/10.1038/s41598-023-32499-3

Ejemplares similares